Completed PHASE2 INTERVENTIONAL 2-arm NCT00800930

Therapeutic Induction of Endogenous Antibiotics

Therapeutic Induction of Endogenous Antibiotics for Improved Recovery in Shigellosis

Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh

Updated 5 times since 2017 Last updated: Dec 6, 2011 Started: Jan 31, 2005 Primary completion: Dec 31, 2008 Completion: Jan 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00800930, this PHASE2 trial focuses on Shigellosis and remains completed. Sponsored by International Centre for Diarrhoeal Disease Research, Bangladesh, it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

International Centre for Diarrhoeal Disease Research, Bangladesh
Karolinska Institutet
Swedish International Development Cooperation Agency (SIDA)

Data source: International Centre for Diarrhoeal Disease Research, Bangladesh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dhaka, Bangladesh